Literature DB >> 17297429

End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage.

Ana M Contreras1, Isaac Ruiz, Gisela Polanco-Cruz, Francisco J Monteón, Alfredo Celis, Gonzalo Vázquez, Efraín Gómez-Herrera, Jesús E García-Correa, René Male-Velázquez, Sara Ruelas-Hernández.   

Abstract

BACKGROUND AND AIM: To what extent the serum levels of alanine aminotransferase (ALT) are related to histological characteristics of liver damage caused by hepatitis C virus (HCV) infection among patients with end-stage renal disease (ESRD) remains unclear.
METHODS: Patients with a positive anti-HCV antibody titer confirmed by supplemental tests were evaluated by liver biopsy. We compared ALT levels in patients with and without renal damage, with similar histological grades and stages of inflammation and fibrosis.
Results: Patients were divided into two groups: patients with ESRD (n = 25) and patients without ESRD renal damage (n = 39).
RESULTS: The ALT level was 42.1 +/- 24.3 IU/L for the ESRD group, compared with 109.9 +/- 55.8 IU/L for the non-ESRD group (P < 0.001). Liver inflammation (modified Knodell grade) was 4.0 +/- 2.1 in the ESRD group versus 5.2 +/- 2.4 in the non- ESRD group; fibrosis (6-point scale) was 1.1 +/- 1.2 versus 1.7 +/- 1.5, respectively.
CONCLUSIONS: Despite histological evidence of liver inflammation, ALT levels in the ESRD group were normal, while ALT levels were significantly higher in the non-ESRD group with similar levels of liver inflammation. In conclusion, ALT levels are not a useful indicator of HCV infection in patients with ESRD and liver biopsies should be recommended for kidney transplant candidates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297429

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  9 in total

1.  Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis.

Authors:  David A Goodkin; Brian Bieber; Michel Jadoul; Paul Martin; Eiichiro Kanda; Ronald L Pisoni
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-01       Impact factor: 8.237

2.  End-stage renal disease and African American race are independent predictors of mild liver fibrosis in patients with chronic hepatitis C infection.

Authors:  F M Aslinia; S K Wasan; A L Mindikoglu; O A Adeyemo; B Philosophe; C Drachenberg; C D Howell
Journal:  J Viral Hepat       Date:  2012-01-16       Impact factor: 3.728

3.  Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C.

Authors:  Chika Nishida; Hirofumi Uto; Makoto Oketani; Koki Tokunaga; Tsuyoshi Nosaki; Mayumi Fukumoto; Manei Oku; Atsushi Sogabe; Akihiro Moriuchi; Akio Ido; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2009-11-05       Impact factor: 7.527

4.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

5.  Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels.

Authors:  Hirofumi Uto; Seiich Mawatari; Kotaro Kumagai; Akio Ido; Hirohito Tsubouchi
Journal:  Hepat Mon       Date:  2012-02-29       Impact factor: 0.660

6.  SASLT practice guidelines: management of hepatitis C virus infection.

Authors:  Abdullah S Alghamdi; Faisal M Sanai; Mona Ismail; Hamdan Alghamdi; Khalid Alswat; Adel Alqutub; Ibrahim Altraif; Hemant Shah; Faleh Z Alfaleh
Journal:  Saudi J Gastroenterol       Date:  2012-09       Impact factor: 2.485

Review 7.  The Pathogenesis of End-Stage Renal Disease from the Standpoint of the Theory of General Pathological Processes of Inflammation.

Authors:  Evgenii Gusev; Liliya Solomatina; Yulia Zhuravleva; Alexey Sarapultsev
Journal:  Int J Mol Sci       Date:  2021-10-23       Impact factor: 5.923

8.  Interaction of Serum Alkaline Phosphatase and Folic Acid Treatment on Chronic Kidney Disease Progression in Treated Hypertensive Adults.

Authors:  Yuanyuan Zhang; Panpan He; Guobao Wang; Min Liang; Di Xie; Jing Nie; Chengzhang Liu; Yun Song; Lishun Liu; Binyan Wang; Jianping Li; Yan Zhang; Xiaobin Wang; Yong Huo; Fan Fan Hou; Xiping Xu; Xianhui Qin
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

9.  Histological and clinical characteristics of patients with chronic hepatitis C and persistently normal alanine aminotransferase levels.

Authors:  Bakht Roshan; Grace Guzman
Journal:  Hepat Res Treat       Date:  2014-05-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.